RoActemra 20 mg/mL concentrate for solution for infusion clinical trials

LOW-DOSE DOBUTAMINE INFUSION AND SINGLE-DOSE TOCILIZUMAB IN ACUTE MYOCARDIAL INFARCTION PATIENTS WITH HIGH RISK OF CARDIOGENIC SHOCK DEVELOPMENT (DOBERMANN) - A 2X2 MULTIFACTORIAL, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

This study, called DOBERMANN, looks at new ways to help patients who have had a heart attack and are at high risk of a serious complication called cardiogenic shock. It tests two medicines to see if they can improve recovery and reduce risks.

A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.

This study looks at different ways to treat early rheumatoid arthritis, comparing standard treatments with newer biologic medicines. It also explores if medicine doses can be lowered for people who are getting better, aiming to find the most effective and safe long-term approaches.

TociCCAre - Randomized, double-blind, multicenter trial of tocilizumab versus placebo in chronic polyarticular inflammatory of calcium pyrophosphate deposition disease refractory to standard treatments

This study is testing a new treatment called tocilizumab for a type of arthritis called chondrocalcinosis, specifically when other treatments haven't worked well. It aims to see if this medicine can reduce pain.

A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.

This study looks at a new treatment called tocilizumab for people who have had a severe stroke. Researchers want to see if this medicine can help limit the size of the stroke damage in the brain. It's compared to a dummy treatment to see if it works.

Non-inferiority study of TOCILIZUMAB in dose-banding versus dose-weight in rheumatoid arthritis with low activity or clinical remission

This study looks at a different way to give RoActemra (tocilizumab) for rheumatoid arthritis. We want to see if giving a standard dose based on how well you're doing, rather than your weight, works just as well for patients with low disease activity or who are in remission.

DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.

This study looks at a new drug, obrixtamig, alongside usual treatment for extensive small cell lung cancer. It aims to see if this new combination helps people live longer and feel better compared to the usual treatment alone.

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).

A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)

A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients with Diffuse Large B-Cell Lymphoma following First-Line Immunochemotherapy and as Monotherapy or In Combination With Polatuzumab Vedotin in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus–Pancreatic Cancer)

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia